βIn short, we are pleased with the biological development during the quarter. This lays the foundation for increased volume and positive cost development in the second half of the year. Financially Q2 2025 was weak, as expected, due to poor price achievement in the quarter,β says Frode Arntsen, CEO of SalMar ASA.
Related Questions
How will the reported strong biological development translate into increased production volume and affect SalMar's supply dynamics in H2 2025?
What are the implications of the weak Q2 financial performance and poor price achievement on SalMar's margins and cash flow outlook?
How does SalMar's biological growth and cost trajectory compare with its main competitors in the aquaculture sector for the upcoming year?